Biocryst Pharmaceuticals Inc (BCRX) concluded trading on Wednesday at a closing price of $10.07, with 4.29 million shares of worth about $43.24 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 43.24% during that period and on May 21, 2025 the price saw a loss of about -2.52%. Currently the company’s common shares owned by public are about 209.21M shares, out of which, 200.47M shares are available for trading.
Stock saw a price change of 2.23% in past 5 days and over the past one month there was a price change of 28.77%. Year-to-date (YTD), BCRX shares are showing a performance of 33.91% which increased to 60.35% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $5.92 but also hit the highest price of $11.11 during that period. The average intraday trading volume for Biocryst Pharmaceuticals Inc shares is 4.67 million. The stock is currently trading 4.57% above its 20-day simple moving average (SMA20), while that difference is up 21.09% for SMA50 and it goes to 26.40% higher than SMA200.
Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) currently have 209.21M outstanding shares and institutions hold larger chunk of about 84.01% of that.
The stock has a current market capitalization of $2.11B and its 3Y-monthly beta is at 1.07. It has posted earnings per share of -$0.26 in the same period. It has Quick Ratio of 2.88. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for BCRX, volatility over the week remained 3.81% while standing at 4.97% over the month.
Stock’s fiscal year EPS is expected to rise by 132.67% while it is estimated to increase by 180.11% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Cantor Fitzgerald on April 29, 2025 offering an Overweight rating for the stock and assigned a target price of $20 to it. Coverage by Wedbush stated Biocryst Pharmaceuticals Inc (BCRX) stock as an Outperform in their note to investors on February 25, 2025, suggesting a price target of $15 for the stock. On November 20, 2023, JP Morgan Resumed their recommendations, while on September 18, 2023, RBC Capital Mkts Upgrade their ratings for the stock with a price target of $10. Stock get a Buy rating from Jefferies on August 04, 2023.
